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INTRODUCTION
Factor VIII (FVIII) is a plasma protein required for normal amplifica-
tion of the intrinsic coagulation cascade and its deficiency causes 
hemophilia A. Severely affected patients are treated with either 
recombinant or plasma-derived FVIII. The pharmacokinetics and 
safety of these products are indistinguishable,1 and their avail-
ability has facilitated the implementation of regular prophylaxis 
as a  therapeutic regime, resulting in better patient outcomes.2,3 
However, production costs are high as a result of several biochemi-
cal characteristics of FVIII. These include inefficient expression of the 
FVIII mRNA,4,5 misfolding and degradation of the primary translation 
product,6,7 retention of the protein in the endoplasmic reticulum8–11 
and the requirement for facilitated transport through the Golgi 
apparatus.12 Once secreted FVIII must be stabilized through interac-
tions with von Willebrand factor (VWF).13
Initial efforts to improve production efficiency centered on 
enhancing the design of the FVIII cDNA. To reduce host cell meta-
bolic load, the nonessential B domain was removed.14 However, 
although not necessary for procoagulant activity,15 evidence sug-
gests that the B domain contributes to biosynthetic regulation by 
participating in quality control during protein synthesis and fold-
ing; shielding the protein from premature proteolysis by thrombin; 
reducing proteolysis by protein C and Factor Xa; and affecting clear-
ance.16 The B domain contains N-linked glycosylation sites that inter-
act with chaperones to facilitate transport through the endoplasmic 
reticulum. Reintroduction of a small portion of the B domain con-
taining six N-linked glycosylation sites has significantly improved 
transport through the endoplasmic reticulum and enhanced the 
level of FVIII secretion.17,18
Low levels of FVIII expression have also plagued preclinical gene 
therapy trials and many of the modifications outlined above have 
been incorporated into various FVIII transgenes. Additionally, 
codon-optimization of the FVIII transgene has been investi-
gated.19–21 Codon-optimization is a strategy in which synonymous 
codons are substituted for those that occur more frequently in 
highly expressed proteins. There is a direct correlation between 
these preferred codons and the relative abundance of correspond-
ing tRNAs.22 However, codon usage bias is species-specific and it is 
thus somewhat surprising that despite adapting usage to a Homo 
sapien bias, optimized FVIII transgenes have been associated with 
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Recombinant FVIII manufacturing is characterized by poor product stability and low yields. Codon-optimization of transgenes 
accelerates translation by exploiting the synonymous codon usage bias of a species. However, this can alter the performance 
of the final product. Additionally, the effects of transgene design across diverse cell types are not well understood and are of 
interest for next-generation protein and gene therapies. To investigate the effects of transgene design across different host cells, 
B-domain-deleted (BDD) and modified codon-optimized (CO-N6) transgenes were inserted via lentiviral delivery into cBOECs, 
HEK293T, and MDCK cells. The CO-N6 cFVIII transgene produced threefold more protein per transgene in HEK293T cells, and 
sixfold more protein in the two canine cell lines. However, pharmacokinetic analysis in hemophilia A dogs demonstrated that 
cFVIII produced from cBOECs transduced with the CO-N6 transgene had significantly reduced in vivo recovery. Furthermore, this 
product showed reduced in vitro stability and activity on thrombin activation versus the BDD product. This trend was reversed in 
HEK293T lines. Overall, our results demonstrate the need for an integrated approach that not only assesses protein expression lev-
els but also considers the influence that host-cells have on preserving the molecular and biochemical properties of the naturally 
occurring FVIII.
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supraphysiological levels of FVIII in hemophilia A mice.19,21 Codon-
optimization of genes is extensively used in the production of many 
recombinant therapeutic proteins. Most of these proteins are pro-
duced in heterologous systems and optimizing human genes for 
these nonhuman expression systems has resulted in significant 
increases in expression.23 Although human recombinant FVIII is cur-
rently produced in heterologous systems, no analysis of the benefits 
of using a codon-optimized (CO) FVIII cDNA for recombinant pro-
duction has ever been reported.
Host-cell engineering and culture optimization are as important 
as transgene design when optimizing large-scale productions of 
therapeutic proteins.24 The preference for mammalian expression 
systems derives from their ability to synthesize proteins that pre-
serve molecular and biochemical properties present in the naturally 
occurring proteins. FVIII requires many post-translational modifica-
tions (PTMs) to produce a fully functional protein and therefore, 
the choice of host cell must be carefully considered since many 
of the enzymes required for correct PTM are species- and tissue-
specific. Alterations to these natural modifications can influence 
immunogen icity25 and avoiding this is critical, since 30% of severe 
hemophilia A patients mount an immune response to their thera-
peutic protein. Therefore, to avoid immunogenic glycosylation pat-
terns from murine cell lines, most recombinant FVIII is synthesized 
in hamster cells. Currently, investigations are underway to evaluate 
the use of immortalized human cell lines,26 but while these may 
eliminate possible species-mismatched glycosylation patterns, 
there is limited evidence that the currently manufactured recom-
binant FVIII products are more immunogenic than the natural FVIII 
isolated from plasma-derived products.27
The therapeutic significance of FVIII for hemophilia A patients, 
along with the technical challenges associated with production have 
consequently positioned FVIII as an important target in a number 
of emerging therapeutic protein technologies.28,29 Combinations of 
emerging technologies are hoped to provide synergistic improve-
ments to recombinant FVIII productivity, stability, and half-life. 
However, the biological consequences of technology combinations 
are poorly characterized. With a view to increasing FVIII expression, 
we modified our canine (c) B domain-deleted (BDD) FVIII transgene 
that was used in an ex vivo gene delivery strategy30 and to produce 
recombinant FVIII for dogs in our hemophilia A colony. These modi-
fications included codon optimization of the transgene and incor-
poration of a truncated region of the canine B domain containing 
six putative N-linked glycosylation sites (N6). In the present study, 
we investigated the effects of these transgene modifications when 
expressed in multiple host cell types, addressing cell line productiv-
ity, characteristics of the recombinant products, and effects on large 
animal pharmacokinetics.
ReSUlTS
Codon optimization of the canine FVIII cDNA
The nucleotide sequence of the cFVIII cDNA31 (Figure 1a) was used to 
generate the BDD cFVIII transgene (Figure 1b). This DNA sequence 
was used for codon optimization and includes the first 269 amino 
acids of the B domain that contains six putative glycosylation sites 
bounded by SQa and SQb19 linker sequences and is referred to as 
CO-N6 (Figure 1c). Both constructs have been incorporated into the 
lentiviral delivery system and are under the control of the ubiqui-
tous EF1α promoter into which an endothelial enhancer element 
(-5.5HSCR) was added.30 A comparison of the CO-N6 cFVIII DNA 
sequence to the nonoptimized BDD sequence using Vector NTI 
software determined that optimization altered 1228 out of 5475 
(23.75%) nucleotides. None of these changes altered any amino 
acids. DNA sequencing and analysis of the entire CO-N6 cFVIII trans-
gene confirmed its integrity and ensured that it encodes a func-
tional cFVIII protein.
Cell lines and protein production
Three host cells, one human (HEK293T) and two canine (cBOECs 
and MDCK), were chosen for recombinant production of cFVIII. 
These cells were transduced with either Lenti-EF1α(–5.5HSCR)-
cFVIII or Lenti-EF1α(–5.5HSCR)-CO-N6-cFVIII and serial dilutions 
of the transduced cells were cultured and expanded for at least 2 
weeks. Cells expressing the highest levels of cFVIII:C were selected 
for further characterization. Levels of cFVIII:C were assessed in 
serum free media after culture for 24 hours and are based on 1 mil-
lion cells (Figure 2a). While levels of cFVIII:C appeared to be higher 
in all cell-types expressing the CO-N6 cFVIII transgene, these levels 
are dependent on integrated transgene copy numbers and there-
fore transgene copy numbers for each cell-type were determined. 
Average integrated copy numbers for BDD-HEK293T and CO-N6-
HEK293T cells were 0.95 or 1.04 copies/cell respectively, and 2.86 
or 0.56 copies/cell respectively for BDD-cBOECs and CO-N6-BOECs. 
Transduction efficiencies were significantly lower with MDCK 
cells with only 5.6 × 10−4 and 6.8 × 10−4 integrated copies/cell in 
BDD-MDCK and CO-N6-MDCK cells. Transgene productivity, as 
Figure 1  The cFVIII proteins produced with the B-domain-deleted (BDD) 
and CO-N6 cFVIII transgenes. (a) A cartoon representation of the wild-
type cFVIII protein showing the domain structure and the boundaries 
of the B domain (Ser734–Gln1639). The MunI restriction sites located 
at amino acids 749 and 1662 were used to remove the B domain. 
(b) The protein encoded by the BDD cFVIII transgene showing the 
three thrombin cleavage sites at R366, R734, and R1681. A portion of 
the B domain (the first 15 amino acids) was retained while the rest of 
the B domain along with the first 15 amino acids of the a3 domain was 
removed. (c) The protein encoded by the CO-N6 cFVIII transgene contains 
the three thrombin cleavage sites. The B domain is bounded by two SQ 
sequences that contain MluI restriction endonuclease sites and a PACE/
furin recognition sequence. The included B domain consists of the first 
269 amino acids and contains six putative N-linked glycosylation sites at 
Asn857, Asn901, Asn1017, Asn1036, Asn1087, and Asn1099.
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represented by cFVIII:C per single integrated transgene, was deter-
mined and fold-increases for the CO-N6 cFVIII transgene relative to 
the BDD cFVIII transgene are shown in Figure 2b. cFVIII:C increased 
by 3.4-, 6.4-, and 6.5-fold in CO-N6-HEK293T, CO-N6-MDCK cells, 
and CO-N6-cBOECs, respectively. The increased expression from the 
CO-N6 transgene in canine cells was significant (P < 0.001) by a two-
way analysis of variance and is consistent with optimization of the 
cFVIII transgene specifically for a canine codon bias.
Cell culture characteristics can directly affect recovered amounts 
of cFVIII and we therefore calculated total recovered cFVIII activity 
based on the surface area of the culture flask (Figure 2c) The higher 
cell densities associated with HEK293T cells made them overall 
more productive for cFVIII:C. cFVIII antigen (cFVIII:Ag) levels were 
measured in culture supernatants after 24 hours in serum-free 
media. Cell productivity for cFVIII:Ag was calculated relative to 1 
million cells (Supplementary Figure 1a) and in contrast to cFVIII:C, 
levels of cFVIII:Ag from CO-N6-cBOECs were significantly less than 
that observed with BDD-BOECs. cFVIII:Ag productivity for a single 
integrated copy of the transgene and relative fold-increases in 
cFVIII:Ag expression were determined (Supplementary Figure 1b). 
Fold-increases in cFVIII:Ag from the CO-N6-HEK293T (2.9-fold) and 
CO-N6-MDCK (5.9-fold) cells were similar to the fold-increases in 
cFVIII:C (Figure 2b). However, only a twofold increase in cFVIII:Ag 
as compared to a 6.5-fold increase in cFVIII:C, was observed with 
CO-N6-BOECs.
Purified recombinant cFVIII from each of the three cell types trans-
duced with either the BDD or CO-N6 transgene were assessed by 
SDS-PAGE (Figure 2d) and although there are similarities between 
the different isolated recombinant cFVIII proteins, each product has 
a distinct protein profile. Different PTMs in the three different host 
cell types, along with the increased size associated with inclusion 
of a portion of the B domain, and variable proteolysis, presumably 
account for the different banding patterns observed on the SDS-
PAGE gel.
The apparent inefficient transduction and very low integrated 
transgene copy numbers in MDCK cells resulted in low levels of 
recombinant cFVIII production. Since significant amounts of cFVIII 
are required for pharmacokinetic evaluation, we chose to exclude 
these cells from further development. In addition, to facilitate treat-
ment-scale production levels of cFVIII by increasing cell density, 
transduced cBOECs were seeded onto collagen-coated microbeads 
and maintained in stirred suspension culture. These cells tolerated 
elevated levels of shear stress, grew readily at high density and cul-
ture supernatant could be continuously recovered.
Pharmacokinetic analysis
Three hemophilia A dogs, two female and one male, each previ-
ously exposed to canine FVIII and weighing approximately 10 kg 
were selected for this study. None of these dogs had evidence of 
Figure 2 A comparison of recombinant cFVIII production from cBOECs, HEK293T, and MDCK cells transduced with either the B-domain-deleted (BDD) 
or CO-N6 cFVIII transgenes. (a) Levels of cFVIII:C produced from host cells transduced with either the BDD or CO-N6 cFVIII transgenes. cFVIII:C was 
measured after 24 hours in serum-free media and is expressed relative to 1 million cells. (b) The fold-increase in cFVIII:C production with the CO-N6 
transgene. Transgene copy numbers were determined for each of the host cells transduced with either the BDD or CO-N6 transgenes and levels of 
cFVIII:C were determined relative to a single integrated copy of the transgene. The fold-increase in cFVIII production for the cells transduced with the 
CO-N6 transgene is expressed relative to the same cell type transduced with the BDD transgene. (c) Cell culture productivity is based on the surface 
area of the culture dish (cm2) and reflects differences in cell size, density and metabolism. All statistical comparisons between cells transduced with 
BDD or CO-N6 were made using an unpaired t-test. Error bars indicate standard deviation and (***) indicates P < 0.001, (**) P < 0.01, and (*) P < 0.05. 
(d) SDS-PAGE of the purified recombinant cFVIII products stained with Coomassie blue. Each of the purified recombinant cFVIII proteins was assessed 
for FVIII activity then diluted and loaded onto a SDS-PAGE gel. The expected molecular size of the single-chain cFVIII is approximately 160 kDa and 
the molecular weight of the additional 269 amino acids of B domain encoded by the CO-N6 cFVIII transgene is expected to be 29.68 kDa. A molecular 
weight marker is in lane 1 with associated molecular weights indicated to the left of each band. It should be noted that in order to visualize cFVIII on 
western blots it was necessary to load approximately twice as much purified protein onto the SDS-PAGE gel.
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neutralizing anti-canine FVIII antibodies. Each dog received 25 units/
kg of each of the recombinant cFVIII products via intravenous infu-
sions over a 5-minute period of time. Blood samples were obtained 
30 minutes 1, 2, 4, 8, 12, 24, and 48 hours later. Clearance was found 
to fit a two-phase exponential decay model for all recombinant 
cFVIII products as well as canine cryoprecipitate (Figure 3a–e). 
Notably, the second dog treated with cFVIII from CO-N6-HEK293T 
cells experienced reduced recovery and delayed peak activity. This 
was associated with a transient decreased heart rate, reduced blood 
pressure, pallor of the mucous membranes, and lethargy. These 
symptoms were observed again following a lower 10 U/kg test dose 
in the dog, and this product was suspended from additional in vivo 
testing (note that all cFVIII preparations were tested for endotoxin 
to ensure final endotoxin exposures of less than 0.2 EU/kg per dog). 
Notably, despite the tendency of some of the dogs in the colony 
to mount an anti-canine FVIII immune response32 none of the dogs 
treated with either the BDD or the CO-N6 products have developed 
inhibitory anti-canine FVIII antibodies. Area-under-the-curve (AUC) 
analysis using the trapezoidal rule (Figure 3f ) indicated significant 
(P = 0.011) reduction in bioavailability of cFVIII from CO-N6-BOECs 
relative to cFVIII from BDD-BOECs. This contrasted with a signifi-
cant (P = 0.032) increase in bioavailability of the cFVIII from CO-N6 
HEK293T compared with cFVIII from BDD-HEK293T. Canine cryopre-
cipitate was prepared as control material and was found to have 
significantly (P = 0.016) higher bioavailability than all of the recom-
binant products tested. Reduced bioavailability was concomitant 
with low incremental recovery (Table 1). Canine cryoprecipitate 
showed a typical incremental recovery of 2.17 (U/dl)/(U/kg). This 
was significantly higher than all of the recombinant products tested 
(P = 0.015). cFVIII from CO-N6-BOECs had a significantly reduced 
recovery relative to the cFVIII isolated from BDD-BOECs (P = 0.008), 
consistent with AUC results.
In vivo procoagulant efficacy of each of the recombinant products 
was also assessed by determining whole-blood clotting times on 
samples taken from each to the time points (Supplementary Figure 
2a–e). Whole-blood clotting times were compatible with the one-
stage cFVIII:C assay results. Reduction in clot time was determined 
as the cumulative decrease in clotting time relative to baseline 
(Supplementary Figure 2f ). These values were determined using 
the trapezoidal rule, analogous to AUC bioactivity described above.
Figure 3 Pharmacokinetics of canine cryoprecipitate and recombinant cFVIII produced from cBOECs and HEK293T cells transduced with either the 
B-domain-deleted (BDD) or CO-N6 cFVIII transgenes (each infusion delivering 25 units/kg). (a–e) Profiles represent the mean FVIII activity over 48 
hours. All recombinant cFVIII products were tested in the same three hemophilia A dogs except for the cFVIII that was isolated from CO-N6 cBOECs 
where safety concerns limited testing to only two dogs. Lines indicate best-fit two-phase exponential decay. (f) Bioavailability by area-under-the-curve. 
Canine cryoprecipitate (Cryo) was isolated from a normal dog. Error bars indicate standard deviation and (*) indicates statistical significance of P < 0.05.
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Table 1 Pharmacokinetic analysis from three hemophilia A dogs treated with recombinant cFVIII derived from different host cells 
 transduced with either the BDD or CO-N6 transgenes
Cryoprecipitate BDD HEK293T CO-N6 HEK293T BDD cBOECs CO-N6 cBOECs
Mean incremental recovery (U/dl)/(U/kg) 2.17 (1.93–2.42) 0.90 (0.62–1.19) 0.96 (0.55–1.38) 1.42 (1.23–1.62) 0.56 (0.27–0.85)
Terminal half-Life (hours) 13.91 6.50 13.76 9.19 14.34
BDD, B-domain-deleted.
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Stability and thrombin activation
To investigate factors that potentially affect pharmacokinetics, we 
assessed in vitro stability, levels of cFVIII activation by thrombin and 
decay of thrombin-activated cFVIII (FVIIIIIa). Stability for the purified 
cFVIII was assessed by incubating each of the products at 37 °C for 2, 
6, and 24 hours in citrated plasma isolated from hemophilia A dogs. 
cFVIII:C was calculated relative to initial values (Figure 4a). After 2 
hours, >90% of the initial cFVIII:C was present in all of the products 
except for the cFVIII isolated from CO-N6-BOECs where only 79% of 
initial activity persisted. This loss in activity was significantly reduced 
(P = 0.023) when compared to the loss in cFVIII:C from the product 
produced in CO-N6-HEK293T. Significant reductions in activity were 
also observed at 6 hours (P = 0.01) and at 24 hours (P = 0.007) with the 
cFVIII produced in CO-N6-BOECs. The remaining cFVIII activity at 24 
hours for all of the recombinant products was <50%, significantly less 
(P = 0.009) than the remaining cFVIII activity (72%) in canine plasma.
The recombinant cFVIII products were analyzed on western 
blots (Figure 4b) and while there are similarities between the size-
distributions of BDD-encoded fragments, the banding patterns for 
CO-N6-encoded fragments are quite different and presumably rep-
resent different post-translational modification between the two 
cell-types. The predicted sizes for thrombin-cleaved A1 (50 kDa), A2 
(43 kDa), and A3/C1/C2 were observed for products derived from 
BDD-HEK293T, CO-N6-BOECs, and CO-N6-HEK293T cells (Figure 4c). 
However, the anti-canine FVIII antibody did not detect any throm-
bin-cleavage products associated with the cFVIII isolated from 
CO-N6-BOECs, even when a 10-fold increase in the amount of cFVIII 
was used (data not shown).
The presence of contaminating activated cFVIII in a purified prep-
aration can result in an overestimation of recovered recombinant 
cFVIII. Although analysis of nonactivated recombinant products 
(Figure 2d and Figure 4b) suggests little or no contaminating acti-
vated cFVIII, we proceeded to confirm this. Purified products were 
incubated for 30 minutes and cFVIII activity, relative to initial values, 
was determined. No rapid loss of activity, associated with contami-
nating activated cFVIII was observed (data not shown). Thrombin-
catalyzed activation of cFVIII (cFVIIIIIa) and rates of decay of cFVIIIIIa 
were examined (Figure 5). The fold-increases in activity after throm-
bin activation for both cFVIII products produced in BDD-HEK293T 
and BDD-BOECs are quite similar (~10-fold) (Figure 5a). However, 
this was not the case for the recombinant cFVIII products produced 
in CO-N6-HEK293T and CO-N6-BOECs. There was a significant dif-
ference (P = 0.0003) between the fold-increase of cFVIIIIIa when 
CO-N6-HEK293T (5.3-fold) and CO-N6-BOECs (31-fold) were used to 
produce the cFVIII. We also evaluated the rates of decay of cFVIIIIIa 
(Figure 5b) and once again the rates were quite similar with the 
recombinant cFVIIIs encoded by the BDD transgene but were signif-
icantly different (P = 0.0028) with the recombinant cFVIIIs encoded 
by the CO-N6 transgene. All the cFVIII products had a greater fold-
increase in levels of thrombin-activation and rate of decay than that 
observed for recombinant human FVIII.
DISCUSSION
Recombinant production of FVIII is complicated by inherent low lev-
els of production and the requirement for PTMs to produce a fully 
functional protein. The need for PTMs limits production of FVIII to 
Figure 4 In vitro stability and thrombin digestion of recombinant cFVIII products. (a) To assess stability, the various recombinant cFVIII products produced 
in HEK293T or cBOECs transduced with either the B-domain-deleted (BDD) or CO-N6 transgenes were incubated at physiological concentration and 
temperature in citrated canine plasma. Remaining cFVIII:C was measured after 2, 6, and 24 hours and values are expressed relative to those observed 
prior to incubation (0 hours). Samples were incubated in triplicate and error bars indicate standard deviation. (b,c) Western blot analysis of recombinant 
cFVIII products incubated without (b) and with (c) thrombin. Molecular size markers are indicated to the right of each blot. Lanes 1 and 2 HEK293T 
cells; Lanes 3 and 4 cBOECs. Lanes 1 and 3, cells transduced with BDD transgene. Lanes 2 and 4, cells transduced with CO-N6 transgene. The bands 
for the single (SC), heavy (HC) and light (LC) chains of cFVIII, as well as the thrombin-activated light chain (LCIIa) and A1 and A2 domains are indicated.
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mammalian cells and currently, most commercially available recom-
binant FVIII products are produced in either CHO or BHK cells. While 
these heterologous cells can carry out PTMs, concern has been 
expressed that subtle differences between the two cell types might 
contribute to observed variable risks of inhibitor development 
between products.27,33,34
We wanted to evaluate the use of a modified cFVIII transgene as a 
way to increase levels of protein production, and to assess whether 
or not different host cells influence the levels of production, integ-
rity, and function of the purified recombinant products. We used a 
lentiviral delivery system to genetically modify cells, since this gene-
integrating platform simplifies evaluation and comparisons of cFVIII 
production from two different cFVIII transgenes expressed in vari-
ous host cells. Finally, pharmacokinetic analysis of each of the prod-
ucts was carried out in the same three hemophilia A dogs, thereby 
eliminating confounding variables such as age, weight, and other 
genetic modifiers of pharmacokinetic behavior. While it would 
appear that use of a CO transgene increases cFVIII production, it 
is important to note that there are other differences between this 
transgene and the original BDD construct that could also account 
for some of this observed benefit. First and foremost, the modified 
transgene includes an additional 269 amino acids from the canine 
FVIII B domain, 6 of which are putative N-linked glycosylation sites 
that have been shown to facilitate FVIII secretion. In addition, it also 
contains an optimized Kozak sequence to enhance translational 
efficiency. In contrast, the BDD transgene only contains 15 amino 
acids from the B domain, none of which are putative glycosylation 
sites. Since the cFVIII transgene was codon optimized for a canine 
bias, it is not altogether surprising that levels of cFVIII expression 
were higher when the modified transgene was expressed in either 
cBOECs or MDCK cells. However, host cell characteristics also 
affected levels of production. Specifically, HEK293T cells are smaller 
and can grow at a much higher density, and these features almost 
certainly contribute to the higher levels of cFVIII produced from 
both BDD-HEK293T and CO-N6-HEK293T cells. Notably, levels of 
cFVIII are higher from BDD-HEK293T cells than CO-N6-BOECs and 
CO-N6-MDCK cells. Production of recombinant canine FVIII was pre-
viously described in baby hamster kidney (BHK) cells stably trans-
fected with a BDD FVIII cDNA.35 This cDNA contains virtually none 
of the BDD36 and yet when expressed in BHK cells is associated with 
higher yields and increased stability relative to a similar human BDD 
construct.
The strategy to modify the original BDD FVIII transgene and to 
use cBOECs was developed with a view to produce an ideal thera-
peutic by balancing improved transgene design with the most 
native-like cellular processing available. BOECs can be readily iso-
lated, transduced to express FVIII and expanded to the numbers 
required for either recombinant protein production or to provide a 
therapeutic benefit in gene delivery strategies. Furthermore, endo-
thelial cells are normally exposed to shear stress, and we used this 
biomechanical influence to enhance levels of cFVIII production by 
seeding transduced cBOECs on collagen-coated microbeads and 
culturing them in spinner flasks. This allowed for extensive expan-
sion of cell numbers and facilitated prolonged and continuous har-
vesting of increased levels of the recombinant cFVIII. In addition, 
we previously demonstrated efficacy with these cells in an ex vivo 
gene delivery strategy in murine37 and canine30 models of hemo-
philia A. We have not yet evaluated the CO-N6 transgene in our ex 
vivo delivery strategy in hemophilia A dogs as the initial trial with 
the BDD FVIII transgene was associated with an anti-FVIII immune 
response. This is an adverse event that has been reported previ-
ously following FVIII gene therapy and is likely not due primarily to 
the use of cBOECs. However, there are also limitations associated 
with the use of BOECs, in particular when these cells are trans-
duced to express FVIII. Despite the fact that endothelial cells are 
the native cells for synthesis of FVIII, and they also produce the VWF 
that protects FVIII from premature inactivation and clearance, we 
have previously found that cBOEC levels of VWF drop rapidly once 
these cells are genetically modified to express high levels of FVIII.30 
Furthermore, we have also observed that elevated levels of cFVIII 
expression in transduced cBOECs are associated with increased 
cBOEC apoptosis.30
Pharmacokinetic profiles showed that cFVIII derived from CO-N6-
cBOECs had poor bioavailability and in vitro evaluations showed 
compromised cFVIII stability and thrombin activation. Since codon 
optimization was not the only modification that was made to the 
CO-N6 transgene, it is not possible to definitively conclude that the 
diminished functional activity of this protein is a direct consequence 
of codon-optimization. However, codon-optimized proteins have 
been shown to exhibit altered function and increased susceptibility 
to protein degradation.35,38–40 The loss of rare codons has been shown 
to cause functional alterations to proteins38,41 as they are thought 
to contribute to pauses during translation, thereby increasing the 
probability of achieving thermodynamically-favored cotransla-
tional folded-states.39 Thus, while the combination of the canine 
CO-N6 transgene expressed in native canine cells is associated with 
increased transgene expression, concordant with more efficient 
protein translation, it may also be associated with aberrant second-
ary or tertiary protein structure. There are several observations that 
support the presence of aberrantly folded cFVIII species in the puri-
fied preparation from CO-N6-cBOECs. First, the polyclonal antibody 
Figure 5 Thrombin activation. Recombinant cFVIII products were 
incubated with or without thrombin for 1 or 30 minutes and levels of 
cFVIII activity were measured using an aPTT-based assay. (a) The fold 
increase in levels of cFVIIIIIa after 1 minute incubation with thrombin 
relative to initial levels of unactivated cFVIII. (b) The rate of decay of the 
various activated recombinant cFVIII products. N = 3 for all experiments. 
Error bars indicate standard deviation and (***) indicates P < 0.001, 
(**) P < 0.01, and (*) P < 0.05.
40
BDD
CO-N6
BDD
CO-N6
30
F
ol
d 
in
cr
ea
se
 F
V
III
lla
20
10
0
40
30
R
at
e 
of
 d
ec
ay
 F
V
III
lla
(I
U
/m
in
ut
e)
20
10
0
Human cBOEC
**
**
*
***
HEK293T
Human cBOECHEK293T
a
b
7
Transgene-host cell interactions in rcFVIII
B Crawford et al.
Molecular Therapy — Methods & Clinical Development (2015) 15033Official journal of the American Society of Gene & Cell Therapy
used to measure cFVIII antigen for the enzyme-linked immunosor-
bent assays as well as the western blot, appears to have a much 
lower affinity for the cFVIII produced in CO-N6-cBOECs. Specifically, 
while there is good correlation between the fold-increases of 
cFVIII:C and cFVIII:Ag with the CO-N6-HEK293T and CO-N6-MDCK 
cells, this correlation does not persist with CO-N6-cBOECs, and sig-
nificantly less than expected cFVIII antigen is detected (we do not 
expect that the cFVIII from CO-N6-cBOECs has an enhanced specific 
activity to explain this altered ratio). Furthermore, thrombin activa-
tion experiments and long-term incubation confirmed altered func-
tion and stability when combining canine codon-optimization with 
the canine translational apparatus, consistent with structural altera-
tions to the protein. However, the most striking evidence of aberrant 
folding in the codon-optimized proteins was the loss of epitopes on 
the recombinant cFVIII produced in CO-N6-cBOECs following high-
concentration thrombin incubation. This suggests that the material 
had increased susceptibility to promiscuous thrombin digestion,40 
or that the digested products were antigenically dissimilar to native 
cFVIII and the other products tested. These aberrantly folded forms 
of cFVIII may have persisted into the final products in the absence 
of affinity purification, and may explain the very low cFVIII activity 
observed. When infused intravenously, active but misfolded forms 
of the recombinant cFVIII might be quickly cleared, resulting in sig-
nificantly reduced recovery levels 30 minutes after injection.
A subset of the design features in the CO-N6 transgene, such as 
the reincorporation of a truncated B-domain,17 may be beneficial 
to recombinant cFVIII product function. The glycosylation profile 
of cFVIII facilitates secretion and is also essential to ensure struc-
tural stability and biological activity. Thromboelastographic stud-
ies showed that the CO-N6-HEK293T and CO-N6-BOEC derived 
cFVIII products produced significantly higher α angle values (a 
descriptor of clot growth rate—not shown) than BDD-HEK293T 
and BDD-BOECs derived cFVIII. Additionally, the terminal half-life 
of cFVIII from CO-N6-HEK293T and CO-N6-BOECs approached that 
of cryoprecipitate. When the remaining activity at 24 hours is con-
sidered relative to peak activity, the cFVIII from CO-N6-cBOECs sig-
nificantly outperforms cFVIII from BDD-HEK293T and BDD-BOECs 
(not shown), despite having reduced recovery. The deletion of the 
B domain in the cFVIII BDD transgene removes 24 amino acids 
of the acidic a3 domain. This region (amino acids 1664–1681) is 
involved in VWF binding. In contrast, it has previously been shown 
that deletion of the FVIII B domain does not affect binding to VWF.42 
Although the VWF binding region and the critical Tyr1673 are not 
removed in our BDD construct they are now directly juxtaposed 
with the proximal region of the remaining B domain and this may 
affect the affinity of the BDD product for VWF. In products isolated 
from HEK293T cells, cFVIII activity was comparable, however the 
CO-N6 product had a greater AUC suggesting a genuinely longer 
half-life. It is noteworthy that we included a putative furin cleav-
age site in the CO-N6 transgene as it was thought to be critical 
for intracellular processing and cleavage of FVIII. However, it has 
very recently been show that furin cleavage actually hampers the 
biological activity of FVIII.43 By every metric tested, the cFVIII from 
CO-N6-HEK293T was superior to the BDD version, demonstrat-
ing both the potential of this transgene and the significant role 
of species- and cell-type specific processing of this recombinant 
protein. The important role of rare codons in directing folding 
pathways provides opportunities to further improve transgene 
design. For example, a map of wild-type gene translation speeds 
could be adapted to the codon bias to improve folding accuracy. 
Additionally, recent kinetic modelling suggests that fast codons 
may also play a regulatory role by rushing the protein through 
functionally useful but thermodynamically unfavored conforma-
tions.44 By preserving slow regions and making fast regions faster, 
it may be possible to develop designs that increase both protein 
yield and quality.
In conclusion, the results that we provide here show that a family 
of products, developed in parallel can provide clues to inform trans-
gene design considerations for recombinant FVIII production and/
or gene therapy.
MATeRIAlS AND MeTHODS
Generation of the BDD and codon-optimized canine FVIII 
transgenes
The canine (c) FVIII cDNA31 (Figure 1a) was used to generate Lenti-EF1α 
(–5.5HSCR)-cFVIII. This construct contains a BDD cFVIII transgene under 
the control of the ubiquitous EF1α promoter into which an endothe-
lial enhancer element was added.30 MunI sites at amino acids (AAs) 749 
and 1,663 were used to remove the B domain while retaining the throm-
bin cleavage sites at AA 734 and 1681 (BDD cFVIII: Figure 1b). This DNA 
sequence was used for codon optimization and additionally includes the 
first 269 amino acids of the B domain that contains six putative glycosyl-
ation sites bounded by SQa and SQb19 linker sequences (CO-N6 cFVIII: 
Figure 1c). The nucleotide sequences directly 5’ to the ATG start of trans-
lation were modified to introduce a Kozak consensus sequence and an 
additional TGA stop codon was added to the 3’ end of the gene. XhoI and 
XmaI restriction sites were added to the 5’ and 3’ ends of the CO-N6 cFVIII 
sequence to facilitate cloning into the lentiviral plasmid. The CO-N6 cFVIII 
cDNA was generated for a canine codon usage bias with GeneOptimizer, 
a proprietary software program developed by GeneArt and was 
 manufactured by GeneArt (Invitrogen, Carlsbad, CA) and cloned into the 
Lenti-EF1α(–5.5HSCR)-cFVIII, thereby replacing the BDD cFVIII transgene 
to generate Lenti-EF1α(–5.5HSCR)-CO-N6-cFVIII.
Genetic modification of host cells to express cFVIII
Lentiviral vectors were produced as described previously.37 Briefly, HEK293FT 
cells (Invitrogen) were cotransfected with pMDLgag/pol RRE, pRSV-Rev, pCI-
VSV-G, and either Lenti-EF1α-(–5.5HSCR)-cFVIII or Lenti-EF1α-(–5.5HSCR)-
CO-cFVIII constructs via calcium phosphate precipitation with 7, 7, 13, and 
40 μg respectively of each plasmid. Viral particles were isolated from con-
ditioned media by ultracentrifugation at 20,000 rpm for 2.5 hours using a 
Beckman SW28 rotor (Beckman Coulter Mississauga, Canada), resuspended 
in 20 mmol/l Tris-HCl with 2 mmol/l MgCl2 and 5% sucrose and stored at −80 
°C. Functional titres were determined as previously outlined.37
cBOECs were isolated as previously described.37 Briefly, buffy coat mono-
nuclear cells isolated from canine venous blood were seeded in MCDB131 
(Invitrogen) supplemented with 2 mmol/l L-glutamine, 100 IU/ml penicillin, 
100 μg/ml, streptomycin, 10% fetal bovine serum, and EGM-2 SingleQuot 
(Lonza, Mississauga, Canada) to a 12-well plate coated with rat tail type-I 
collagen (BD Biosciences, Mississauga, Canada). Colonies with endothelial 
morphology formed within 2–3 weeks, becoming confluent approximately 
10 days later. MDCK cells (ATCC; cat. CCL-34) and HEK293T cells were cul-
tured in  Dulbecco’s Modified Eagle’s medium high glucose (Corning, 
Tewksbury, MA) with 10% fetal bovine serum. cBOEC, HEK 293T, and MDCK 
cells were transduced at multiplicities of infection between 5 and 250 using 
a Viraductin Lentivirus Transduction kit (Cell Biolabs, San Diego, CA) and 
expanded. To determine levels of cFVIII expression, type-I collagen-coated 
six-well plates were seeded overnight with 106 cells per well for each combi-
nation of multiplicities of infection, transgene, and parental cell type, rinsed 
in Hank’s buffered salt solution and incubated for 24 hours in serum-free 
expression media. Expression media used for MDCK cells was MDCKUltra 
medium (Lonza), and for HEK293T cells it was  Dulbecco’s Modified Eagle’s 
medium/F12 without phenol red medium supplemented with 2 mmol/l 
L-glutamine, 2.5 mmol/l CaCl2, insulin-transferrin-selenium, and 1 mg/ml 
Albumax (Invitrogen). cBOEC expression media comprised endothelial basal 
medium without phenol red (Lonza) supplemented with EGM-2 (exclud-
ing fetal bovine serum), 100 IU/ml penicillin, 100 μg/ml streptomycin, 2.5 
mmol/l CaCl2 insulin-transferrin-selenium, and 1 mg/ml Albumax. FVIII activ-
ity in expression media was measured with a one-stage assay on an STA 
compact hemostasis system (Stago) from three on-board dilutions against 
a standard curve of normal canine pooled plasma. Plates were then trypsin-
ized and cells were counted in a hemocytometer. The most productive cell 
lines were expanded and stored.
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Production and purification of recombinant cFVIII
For large scale-productions, HEK 293T cells were cultured in 500 cm2 triple 
T-flasks (Sigma-Aldrich, Oakville, Canada), using the expansion and expression 
media described above and harvested daily for 2–3 days. cBOEC were expanded 
in static culture to 5 ×·107 cells and subsequently seeded onto 5 g of Cytodex 3 
collagen-coated microbeads (Sigma-Aldrich) prepared according to the manu-
facturer’s instructions. Cells were expanded to confluency in a 1 l spinner flask 
(Bellco Glass, Vineland, NJ), using the serum-free medium described above. 
Confluent beads were washed three times in Hank’s buffered salt solution, and 
resuspended in the BOEC serum-free expression medium described above and 
harvested daily for 2–3 days. Conditioned expression media was supplemented 
with 10 μm Amidophenylmethanesulfonyl fluoride and 1 mmol/l benzamidine, 
then passed through a 0.45 μm Steritop vacuum filter (Millipore, Etobicoke, 
Canada). Filtrate was purified as described previously35 with minor modifica-
tion. Briefly, filtrate was loaded onto a 50 ml SP-Sepharose Fast Flow column (GE 
Healthcare, Mississauga, Canada) equilibrated with 20 mmol/l 2-(N-morpholino)
ethanesulfonic acid (MES), 0.15 M NaCl, 5 mmol/l CaCl2, 0.01% Tween-80 (Sigma-
Aldrich), pH 6.8. The column was washed with buffer and eluted 20 mmol/l MES, 
0.65 M NaCl, 5 mmol/l CaCl2. Following one-stage clotting assay, fractions with 
cFVIII activity were stored at −80 °C. Fractions from successive daily harvests 
were thawed, pooled, and diluted with 20 mmol/l 4-(2-hydroxyethyl)-1-pipera-
zineethanesulfonic acid (HEPES), 5 mmol/l CaCl2, pH 7.4. The diluate was loaded 
on 5 ml Q-Sepharose Fast Flow column (GE Healthcare) equilibrated with the 
same buffer. The column was washed with buffer and eluted with 20 mmol/l 
HEPES, 5 mmol/l CaCl2, 0.65 M NaCl pH 7.4. Fractions were supplemented with 
3% sucrose and stored at −80 °C in small aliquots. Products were assayed for 
endotoxin using a chromogenic Limulus Amebocyte Lysate assay (Thermo 
Scientific, Mississauga, Canada), to ensure final exposures of less than 0.2 EU/
kg per dog. Lot concentrations were determined by diluting the products 1:100, 
1:200, and 1:400 in severe hemophilic dog plasma prior to one-stage clotting 
assay as described above. HEK293T, cBOECs, and MDCK host cells transduced 
with the BDD transgene are referred to as BDD-HEK293T, BDD-BOECs, BDD-
MDCK respectively, while the same cells transduced with the CO-N6 transgene 
are referred to as CO-N6-HEK293T, CO-N6-BOECs, CO-N6-MDCK respectively.
Functional cFVIII and antigen assays
Levels of cFVIII activity (cFVIII:C) were measured with a one-stage activated 
partial thromboplastin time-based assay using a STA compact hemosta-
sis system (Stago, Toronto, Canada) from three on-board dilutions against 
a standard curve of normal canine pooled plasma. When necessary, cFVIII 
samples were diluted in canine deficient plasma. cFVIII and cVWF antigens 
were quantified by enzyme-linked immunosorbent assay as previously 
described30 using a polyclonal sheep anti-cFVIII antibody (SAC8C-IG; Affinity 
Biologicals, Ancaster, Canada) and a polyclonal rabbit anti-human VWF anti-
body (Dako, Mississauga, Canada) that cross reacts with canine VWF antigen 
(Dako). Normal canine pooled plasma was used to generate the standard 
curve. The anti-cFVIII antibody used in our canine FVIII enzyme-linked immu-
nosorbent assay was generated against cFVIII produced from our BDD cFVIII 
transgene product and should therefore not interact with the B domain of 
the full-length native FVIII in the pooled plasma.
Animals
The previously described32,45 hemophilia A dog colony is housed at Queen’s 
University in facilities that are accredited by the Canadian Council for Animal 
Care. All procedures were approved by the Queen’s University Animal Care 
Committee.
Pharmacokinetics
Production of normal canine cryoprecipitate and measurement of whole-
blood clotting times were completed according to standard protocols. 
Following a 2-week washout period, three dogs were each treated with 25 U/
kg of FVIII, derived from cryoprecipitate and each of the recombinant cFVIII 
products. Blood samples were obtained via the saphenous vein. Parametric 
pharmacokinetic analysis was modeled with simple one-phase-exponential 
decay. Nonparametric area-under-the-curve was calculated using the trap-
ezoidal rule.46 Curve-fitting, two-way analysis of variance, and t-tests were 
conducted with Prism 4 (GraphPad, La Jolla, CA).
Activation of recombinant FVIII with thrombin
cFVIII samples were diluted to 0.3–0.5 U/ml in 20 mmol/l HEPES, 150 mmol/l 
NaCl, 4 mmol/l CaCl2, 10 g/l bovine serum albumin, pH 7.4 in a final volume 
of 200 μl. To each sample, 1 μl of a 1.2 U/ml Recothrom (Bayer, Mississauga, 
Canada) solution was added, vortexed, and incubated in a water bath at 
37 °C for 1 or 30 minutes. Volumes of 20 μl were removed, 6 μl of 36 U/ml 
hirudin (ProspecBio, East Brunswick, NJ) were added and after vortexing, 
samples were diluted 10-fold to ensure negligible amounts of hirudin were 
carried into the one-stage activated partial thromboplastin time-based 
assay.47 Samples were immediately assayed for cFVIII:C. Controls were incu-
bated without thrombin and were used to calculate levels of activation of 
cFVIII by thrombin.
Stability of recombinant cFVIII
To evaluate stability, aliquots of the purified recombinant cFVIII were diluted 
1:100 in canine hemophilic plasma, incubated at 37 °C in a water bath for 2, 
6, or 24 hours and cFVIII:C was immediately assessed.
SDS-PAGE and western blot analysis
The various recombinant cFVIII proteins were diluted to approximately 10 
μg in deionized water and incubated at 37 °C for 30 minutes with dithio-
threitol and 3× SDS sample loading buffer (New England Biolabs, Whitby, 
Canada). Proteins were separated on a 10% acrylamide Next Gel (AMRESCO, 
Solon, OH), and electroblotted in running buffer without methanol to a poly-
vinylidene fluoride membrane with 0.2 μm pore size in a Mini-Protean three-
cell electrophoresis system (Bio-Rad, Mississauga, Canada). Membranes 
were blocked with 5% skim milk powder in Tris-buffered saline and probed 
with a peroxidase-conjugated sheep anti-canine FVIII antibody (Affinity 
Biologicals). Following washing with 0.1% Tween-20 in Tris-buffered saline, 
membranes were rinsed in Tris-buffered saline then Western Lightning 
ECL chemiluminescent substrate (PerkinElmer, Woodbridge, Canada), 
and imaged in a FluorChem IS-8900 imaging system (Alpha Innotech, San 
Leandro, CA) over a 15-minute exposure. For thrombin digestion of cFVIII, 5 
μl samples were preincubated for 15 minutes in 1.2 IU Recothrom.
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